# LifeMD, Inc.: Form 10-Q for the period ended Mar 31, 2014

- Company: [LifeMD, Inc.](/companies/lfmd.md) (CIK 948320)
- Form: 10-Q
- Filed: 2014-05-15
- Accepted by EDGAR: May 15, 2014, 16:11 ET
- Period: 2014-03-31
- Accession: 0001213900-14-003384
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/948320/000121390014003384/f10q0314_immudyne.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/948320/000121390014003384/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2014-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2014-01-01 to 2014-03-31 | $192.4k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2014-01-01 to 2014-03-31 | $49.1k | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2014-01-01 to 2014-03-31 | $143.3k | us-gaap:GrossProfit |
| Operating income | 3 months, 2014-01-01 to 2014-03-31 | −$177.6k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2014-01-01 to 2014-03-31 | $478 | us-gaap:InterestExpense |
| Net income | 3 months, 2014-01-01 to 2014-03-31 | −$140.9k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2014-01-01 to 2014-03-31 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months, 2014-01-01 to 2014-03-31 | −$6.6k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2014-03-31 | $36.4k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2014-03-31 | $241.1k | us-gaap:AssetsCurrent |
| Total assets | at 2014-03-31 | $327.5k | us-gaap:Assets |
| Current liabilities | at 2014-03-31 | $218.9k | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2014-03-31 | $245.0k | us-gaap:Liabilities |
| Shareholders' equity | at 2014-03-31 | $82.5k | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 20,076 characters.

### Safe Harbor Declaration

### Overview

We manufacture, distribute and sell natural immune support products. Beta glucans are a natural extract that has been shown through testing and analysis and scientific research to support the immune system. Our core nutraceutical and cosmetic product lines consist of yeast beta glucans in oral and topical applications. Our natural immune support products are manufactured in a current good manufacturing practices (“cGMP”) facility. Yeast beta glucans are classified as GRAS by the FDA. Historically, we have sold our products primarily on a word-of-mouth basis through distributors and our website as standalone product lines, as well as business-to-business as dietary supplement and a cosmetic enhancement, and as a feed-additive for animal use. As of 2011, we began exiting this lower-margin market for feed-additive products, which exit we completed in 2013. Our sales and marketing efforts going forward are concentrated on our oral and topical-use products for healthcare professionals, distributors and direct-to-consumer sales. However, based on the Company’s cash balance at March 31, 2014 and projected cash needs for the remainder of 2014, we estimate that we will need to raise additional capital to cover operating and capital requirements for the 2014 year.

Significant factors that we believe could affect our operating results are (i) marketing and advertising expenses; (ii) protection of our intellectual property rights; (iii) imposition of more stringent government regulations of our products; and (iv) lack of adequate capital to effectuate our business plans.

Our marketing strategy is to promote sales of our oral and topical-use products, which constitute our core business. We intend to capitalize on our development of proprietary and patented products and by focusing on commercializing sales on a more meaningful, global basis. We expect that a significant component of our selling, general and administration expenses going forward will consist of marketing and advertising expenses to increase our sales. The primary components of our marketing and advertising expenses may include online sales promotions through our website, trade advertising, direct marketing to nutraceutical companies and industry associations, consumer research and search engine and digital advertising. We expect our selling, general and administrative expenses to increase in absolute dollars as we incur increased costs related to our marketing strategy and growth of our business. These costs, along with the additional costs resulting from our operations as a public reporting company, could impact our future operating profitability.

We historically have expended a significant amount of our funds on obtaining and protecting our patents, trade secrets and proprietary products. We rely on the patent and trademark protection laws in the U.S. to protect our intellectual property and maintain our competitive position in the marketplace. For several years, we were involved in complex litigation regarding patents and licenses critical to our products. In 2010, we prevailed on all major legal matters and reached favorable settlements. If additional litigation becomes necessary to protect our intellectual property rights, such litigation may be costly, divert our management’s attention away from our core business and have a negative impact on our operations. Furthermore, there is no guarantee that litigation would result in an outcome favorable to us.

Yeast beta glucans are designated as GRAS under current FDA regulations. Future government regulations may prevent or delay the introduction or require the reformulation of our products. Some agencies, such as the FDA, could require us to remove a particular product from the market, delay or prevent the import of raw materials for the manufacture of our products or otherwise disrupt the marketing of our products. Any such government actions could result in additional costs to us, including reduced growth prospects, lost sales from products that we are required to remove from the market and potential product liability litigation.

We have limited operating capital and have funded operations in the past through the sales of our products and loans and advances from Mark McLaughlin, our President, and other directors. While we believe that we will begin to generate increased sales, it is likely that we will require additional operating capital to continue operations through the balance of 2014. Until we are in a position to obtain such capital from revenues to meet our normal business obligations, the Company will have to depend on sources other than operating revenues to meet our operating and capital needs. No assurance can be given that such sources will be available and no assurance can be given that Mr. McLaughlin or other directors who have in the past willingly funded operations will commit to do so in the future, or that the Company will be successful in its endeavors to raise additional capital. For additional information regarding these and other risks please see our Annual Report on Form 10K for the fiscal year ended December 31, 2013 filed with the SEC on March 28, 2014.

### Results of Operations

### Three Months Ended March 31, 2014, Compared to the Three Months Ended March 31, 2013

The following table sets forth the results of our operations for the periods indicated as a percentage of net sales:

|  | 2014 $% of Sales |  | 2013 $% of Sales |  |
| --- | ---: | ---: | ---: | ---: |
| Sales | 192,429 | - | 230,258 | - |
| Cost of sales | 49,090 | 25.5% | 52,900 | 23.0% |
| Gross profit | 143,339 | 74.5% | 177,358 | 77.0% |
| Operating expenses | (320,977) | (167 ) % | (248,145) | (107.8 ) % |
| Loss from operations | (177,638) | (92.5 ) % | (70,787) | (30.8 ) % |
| Other income | 32,399 | 16.8% | 25,000 | 10.9% |
| Income tax benefit | 4,300 | 2.5% | 4,300 | 1.9% |
| Net loss | (140,939) | (73.2 ) % | (41,487) | (18.0 ) % |

Sales for the first quarter of 2014 were $192,429, a decrease of 16.4% from $230,258 for the same period in 2013. Our sales decreased as a customer who has historically accounted for more than 10% of our sales delayed certain orders that it typically placed in the first quarter to the second quarter of our fiscal year, due to the customer holding inventory of our product at the end of the 2013 fiscal year.

Cost of sales consists primarily of material costs, labor costs and related overhead directly attributable to the production of our products. Total cost of sales decreased 7.2% to $49,090 in the first quarter of 2014 compared to $52,900 for the same period in 2013. The decrease in our cost of sales was primarily attributable to our overall sales decrease.

Gross profit decreased 19.2% to $143,339 in the first quarter of 2014 compared to $177,358 for the same period in 2013 as result of our decreased sales. Gross profit as a percentage of sales decreased slightly to 74.5% from 77.0% as a result of the overhead expenses we typically incur matched with our lower sales volume.

Operating expenses consisted of general and administrative expense, compensation and related expense and professional fees. Operating expenses increased 29.4% to $320,977, in the first quarter of 2014 compared to $248,145 for the same period in 2013. General and administration expense increased by 25.6% to $102,363 compared to $81,513 for the same period in 2013 due to increased marketing expenses incurred to establish brand awareness for our legacy and new products. Compensation and related expenses increased by 36.8% to $164,021 in 2014, compared to $119,891 in 2013, due primarily to compensation paid to our chief marketing officer and the retention of a digital marketing consultant. Professional fees increased 16.8% to $54,593 in 2014, compared to $46,741 in 2013, as a result of an increase in legal expenses in the first quarter of 2014.

Other income, net, increased by $7,399 in 2014 resulting from the write-off of an old accounts payable.

Our net loss for the first quarter of 2014 was $140,939 compared to net loss of $41,487 for the same period in 2013, an increase of $99,452 or 240%. Net loss as a percentage of sales was 73.2% in the first quarter of 2014 compared to net loss as a percentage of sales of 18.0% for the same period in 2013. Our increased net loss was attributable to our decrease in sales and our increased operating expenses, which in turn were due to our additional expenditures in the first quarter of 2014 on marketing our products.

### Liquidity and Capital Resources

Our principal demands for liquidity are to increase sales, purchase inventory and for sales distribution and general corporate purposes. We incurred negative cash flows in 2012 and 2013 and may not have sufficient financial resources to fund operations through December 31, 2014. As a result, our auditors have raised substantial doubt about our ability to continue as a going concern. Based on our cash balance at March 31, 2014 and projected cash needs for the remainder of 2014, we will need to raise additional capital to cover operating and capital requirements for the 2014 fiscal year. We plan on raising the additional needed funds through increased sales volume, issuing additional shares of common stock or other equity securities, or obtaining debt financing. In 2013 and 2012, we raised $175,000 and $345,883, respectively, through sales of our common stock in private placements, as well as proceeds from the exercise of stock options. Historically, we also have funded operations through loans and advances from our directors and officers.. Although we have been successful to date in raising necessary funding, there can be no assurance that required future financing can be successfully completed on a timely basis, or on terms acceptable to us. Any future issuance of equity securities could cause dilution to our shareholders. Any incurrence of indebtedness could increase our debt service obligations and cause us to be subject to restrictive operating and financial covenants.

We had net working capital of $22,169 at March 31, 2014, resulting in an increase of $1,810 from net working capital of $20,359 at March 31, 2013. The ratio of current assets to current liabilities was 1.1 to 1 at March 31, 2014.

The following is a summary of cash provided by or used in each of the indicated types of activities during the three months ended March 31, 2014 and 2013:

| Cash provided by (used in): | 2014 | 2013 |
| --- | ---: | ---: |
| Operating activities | $(6,647) | $(60,013) |
| Financing activities | (12,000) | - |

Net cash flow used in operating activities was $6,647 for the three months ended March 31, 2014, compared to net cash flow used in operating activities of $60,013 for the same period in 2013. The decrease in net cash outflow in operating activities was attributable primarily to our receipt of legal settlement proceeds in the first quarter of 2014.

Net cash flows from financing activities was $12,000 in 2014 for the repayment of a note payable issued by one of our directors.

### Private Placements

In June 2013, we issued 500,000 shares of our common stock (and three-year warrants to purchase 250,000 shares of our common stock at $0.40 per share) to accredited investors at $0.25 per unit for $125,000 in gross proceeds.

### Indebtedness

From time to time, our directors, officers and other related individuals have made short-term advances to us for our operating needs. At December 31, 2013, notes payable due to officer and other related individuals totaled $40,200. During the quarter ended March 31, 2014, a total of $12,000 was repaid. Interest expense on notes payable amounted to $478 for the quarter ended March 31, 2014.

We are subject to a royalty agreement pursuant to which we are required to pay a monthly royalty of 8% on all sales of certain skin care products up to $227,175. At March 31, 2014, we included $102,000 in accounts payable and accrued expenses relating to this royalty agreement, with the remaining commitment under the royalty agreement at approximately $51,000. Our President, Mr. McLaughlin, has a 60% interest in the royalties paid under the agreement and has voluntarily deferred payments due without interest until we have the financial wherewithal to pay such royalties.

### Legal Matters

In October 2013, the Company agreed to a judgment against the estate of a former officer and related individuals in connection with a judgment in favor of the Company rendered in June 2000, finding that defendants in question had failed to use their best efforts in support of the Company in violation of an agreement between the parties. Subsequently, a settlement was reached with these parties in the amount of $386,000. During the year ended December 31, 2013, the Company received net proceeds of $78,000 and the balance, $132,000, net of related legal costs, in March 2014.

In November 2005, we filed suit in Texas against Biopolymer Engineering, Inc. d/b/a Biothera who was claiming ownership of certain patents we own covering our yeast beta glucan products. Biothera subsequently filed suit against us in Federal Court in Minnesota alleging infringement of the same patents. The state court case proceeded to trial in which it was adjudicated that we were the owner of all of the patents at issue. In November 2009, we entered into a settlement agreement that resolved all litigation aspects of the federal and state court proceedings. The settlement agreement stipulated that we were the owner of all of the patents at issue. As part of the settlement agreement, we received $440,000 as reimbursement for litigation costs. In addition, we were awarded $200,000 in eight installments of $25,000 every six months beginning on January 15, 2011, in return for an exclusive patent license to Biothera for U.S. Patent No. 5,702,719, covering our beta glucan derived from yeast for dermatological and nutritional use. The term of the license agreement is consistent with the term of the $25,000 semi-annual payments. The $25,000 installments are being recorded as revenue only upon receipt of the funds. At March 31, 2014, $25,000 remained to be paid to us under this agreement.

### Off-Balance Sheet Arrangements

There are no off-balance sheet arrangements between us and any other entity that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to shareholders.

We have not entered into any financial guarantees or other commitments to guarantee the payment obligations of any third parties. We have not entered into any derivative contracts that are indexed to our shares and classified as stockholders’ equity or that are not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research and development services with us.

### Critical Accounting Policies

While our significant accounting policies are described more fully in Note 2 to our financial statements, we believe the following accounting policies are the most critical to aid you in fully understanding and evaluating this management discussion and analysis.

#### Basis of Presentation and Use of Estimates

The accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the U.S., or U.S. GAAP. In preparing financial statements in conformity with U.S. GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant estimates required by management include the valuation of inventory and stockholders’ equity-based transactions. Actual results could differ from those estimates.

#### Inventory

Inventory is valued at the lower of cost or market value with cost determined on a first-in, first-out basis. Management compares the cost of inventory with the net realizable value and an allowance is made for writing down their inventories to market value, if lower.

#### Revenue Recognition

The Company’s policy is to record revenue as earned when a firm commitment, indicating sales quantity and price exists, delivery has taken place and collectability is reasonably assured. The Company generally records sales once the product is shipped to the customer. If applicable, provisions for discounts, returns, allowances, customer rebates and other adjustments are netted with gross sales. The Company accounts for such provisions during the same period in which the related revenues are earned. Customer discounts, returns and rebates have not been significant.

Delivery is considered to have occurred when title and risk of loss have transferred to the customer. Sales to international distributors are recognized in the same manner. If title does not pass until the product reaches the customer’s delivery site, then recognition of revenue is deferred until that time. There are no formal sales incentives offered to any of the Company’s customers. Volume discounts may be offered from time to time to customers purchasing large quantities on a per transaction basis. There are no special post shipment obligations or acceptance provisions that exist with any sales arrangements

#### Stock-based Compensation

The Company follows the provisions of ASC 718, “Share-Based Payment”. Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized over the respective vesting periods. The fair value of options at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and represents the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility of our shares using weekly price observations over an observation period that approximates the expected life of the options. The risk-free rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar to the expected option life. The estimated forfeiture rate included in the option valuation was zero.

Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.

### New Accounting Pronouncements

Accounting standards that have been issued or proposed by the FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption.

### Going Concern

Based on the our cash balance at March 31, 2014 and projected cash needs for the remainder of 2014, management estimates that it will need to raise additional capital to cover operating and capital requirements for the 2014 year. Management plans on raising the additional needed funds through increased sales volume, issuing additional shares of common stock or other equity securities, or obtaining debt financing. Although we have been successful to date in raising necessary funding, there can be no assurance that required future financing can be successfully completed on a timely basis, or on terms acceptable to the Company.

The Company's continued operations are dependent upon obtaining an increase in its sales volume and the continued financial support from officers and directors or the issuance of additional shares of common stock.

## Controls and procedures

As filed, 2,713 characters.

### Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our Principal Executive Officer (“PEO”), who is also our Principal Financial Officer (“PFO”), of the design and effectiveness of our “disclosure controls and procedures” (as defined under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered by this report. Based on this evaluation, our PEO/PFO concluded that as of the end of the period covered by this report, these disclosure controls and procedures were not effective. The conclusion that our disclosure controls and procedures were not effective was due to the presence of the following material weaknesses in disclosure controls and procedures which are indicative of many small companies with small staff: (i) inadequate segregation of duties and effective risk assessment as the Company had only one officer; (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC Guidelines; and (iii) inadequate security and restricted access to computer systems including insufficient disaster recovery plans; and (iv) no written whistleblower policy. Our PEO/PFO plans to implement appropriate disclosure controls and procedures to remediate these material weaknesses, including (i) appointing additional qualified personnel to address inadequate segregation of duties and ineffective risk management; (ii) adopt sufficient written policies and procedures for accounting and financial reporting and a whistle blower policy once funds are available; and (iii) implement sufficient security and restricted access measures regarding our computer systems and implement a disaster recovery plan.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the quarter ended March 31, 2014, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

## Risk factors

As filed, 145 characters.

You should consider carefully the factors discussed in the “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2013.

Filed May 15, 2014.
Source: SEC EDGAR, the filing index for accession 0001213900-14-003384. Last ingested by Listed: Nov 13, 2026, 16:33 ET. No prices; not investment advice.
